Biomea Fusion Inc (BMEA) - News Archive

Abstract: The 2025 European Hematology Association (EHA) conference highlighted a pivotal advancement in acute leukemia treatment, specifically targeting patients with FLT3-mutant acute myeloid leukemia (AML). Biomea Fu...

Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for diabetes, obesity, and genetically defined cancers, has embarked on a strategic...

In a significant stride towards advancing diabetes treatment, Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company committed to the development of innovative therapeutic solutions, has announce...

: Biomea Fusion, a clinical-stage biopharmaceutical enterprise, is making strides in the development of novel therapies aimed at genetically defined cancers and metabolic diseases. Recent announcements from Biomea Fusio...

Biomea Fusion Secures Talent with Stock Option Grants Amid Expanding Focus on Metabolic Diseases and CancersREDWOOD CITY, Calif. December 2, 2024 In a strategic move to attract and retain key talent, Biomea Fusion, Inc....

Late-Breaker Oral Presentation Unveils New Insights from COVALENT-111 In a significant development for diabetes management, a late-breaker oral presentation showcased new analyses from the escalation portion of the COVA...

In a noteworthy development for the biopharmaceutical landscape, Biomea Fusion, Inc. has announced the lifting of the FDA s clinical hold on its investigational covalent menin inhibitor, BMF-219. This decision paves the...

Biomea Fusion, Inc. Continues to Grant Inducement Options to Employees, Bolstering Growth in Clinical Stage Biopharmaceutical CompanyBiomea Fusion, Inc. (Nasdaq: BMEA) has once again demonstrated its commitment to attra...

CSIMarket.com presents an analysis of recent articles, shedding light on the current state of Biomea Fusion Inc and its position within the pharmaceutical industry. The articles offer insights into ongoing investigation...

Biomea Fusion Inc (BMEA) has recently been in the spotlight, with various legal actions and market trends affecting its performance. Shareholder claims have prompted investigations by renowned law firms, while hedge fun...

Biomea Fusion Inc, a prominent clinical-stage biopharmaceutical company, has experienced a series of events that have significantly impacted its stock performance and raised concerns among investors. In this article, we...

Biomea Fusion s BMF-219 in Diabetes Placed on Clinical HoldIn a recent press release, Biomea Fusion, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the Phase I/II clin...

Biomea Fusion, Inc., a prominent clinical stage biopharmaceutical company, has recently made an announcement regarding an inducement grant made to a new employee. The grant includes non-qualified stock options to purcha...

Biomea Fusion, a biopharmaceutical company focused on developing innovative therapeutics, recently announced the successful completion of enrollment in the first three arms of the Phase 2 expansion cohorts for their inv...

Increased Stock Option Grants at Biomea Fusion Inc. Reflect Commitment to Employee Retention and Growth StrategyBiomea Fusion, Inc. (Nasdaq: BMEA) continues to demonstrate its dedication to attracting and retaining top...

Biomea Fusion, a renowned clinical stage biopharmaceutical company, has recently made a significant announcement regarding the granting of non-qualified stock options to two new employees. The options allow the purchase...

Revolutionary Breakthrough in Diabetes Treatment: Biomea Fusion s BMF-219 Shows Promising Results in Regenerating Insulin-Producing Beta CellsIn a groundbreaking development for the field of diabetes research, Biomea Fu...

Combining the forces of cutting-edge research and medical innovation, Biomea Fusion has recently announced a significant milestone in their Phase II clinical trial, COVALENT-112. The study marks the dosing of the first...

In the field of medical advancements, one particular research and development company, Biomea Fusion, is garnering significant attention with their groundbreaking investigational drug, BMF-219. Recently, Biomea Fusion a...

Biomea Fusion, a leading biopharmaceutical company, recently presented long-term follow-up data demonstrating improved glycemic control in adults with Type 2 Diabetes after 22 weeks off treatment. This groundbreaking re...